雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

An interim report on the safety and efficacy of latanoprost and timolol maleate(Xalacom® combination ophthalmic solution) Ai Yoshida 1 , Mika Morimasa 1 , Etsuya Bando 1 , Toshiya Watanabe 1 , Aya Komatsubara 1 , Yutaka Endo 1 1Development Operations, Development Japan, Pfizer Japan. Jnc pp.573-580
Published Date 2014/4/15
DOI https://doi.org/10.11477/mf.1410105204
  • Abstract
  • Look Inside
  • Reference

Abstract. Background:Xalacom® combination ophthalmic solution contains 50 ng latanoprost and 5 mg timolol maleate per ml. It is indicated for glaucoma or ocular hypertension. Purpose:To present a clinical data regarding safety and efficacy of Xalacom® ophthalmic solution. Cases and Method:This prospective study was made on patients who received Xalacom® ophthalmic solution in 116 institutions over a 2-year period. Out of 659 cases initially enrolled in the project, data were obtained on 473 eyes of 473 patients. There were 225 males(47.6%)and 248 females(52.4%). The age averaged 67.4±12.6 years. The series comprised primary open-angle glaucoma 46.1%, normal-tension glaucoma 42.8%, primary closed angle glaucoma 4.8%, secondary glaucoma 3.5%, and other glaucomas 2.9%. Results:Adverse drug reaction occurred in 47 cases(9.9%), including eye irritation 13 cases, puntate keratopathy 9 cases and corneal problems 4 cases among others. Adverse reactions were significantly associated with eye complications(p=0.045)and past eye history(p=0.025). When judged by each attending physician, the treatment was effective in 400 cases(84.6%). No statistical evaluation was made between intraocular pressure and type of glaucoma during the initial 52 weeks of treatment. Conclusion:Xalacom® ophthalmic solution was safe and effective, in general, for glaucoma including ocular hypertension.


Copyright © 2014, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

もっと見る

文献を共有